{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-425684","form_type":"8-K","ticker":"ODTX","cik":"0001882782","company_name":"Odyssey Therapeutics, Inc.","filed_at":"2026-10-20T11:00:21+00:00","discovered_at":"2026-10-20T11:05:01.360961+00:00","generated_at":"2026-10-20T11:05:20.587906+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Odyssey OD-001 Phase 2a UC induction: 27% clinical remission at 20mg BID; primary endpoint met","bullets":["Primary endpoint met: mean 2.4-point reduction in modified Mayo score at Week 12 across 56 efficacy-evaluable patients (p<0.001).","20 mg BID (n=41): clinical remission 27%, clinical response 61%, symptomatic remission 49%; 10 mg BID (n=15): 20%, 40%, 27%.","At 20 mg BID, hsCRP and circulating neutrophils fell significantly and serum albumin rose; remission was 16% in MES 3 patients (n=19) and 29%/23% in therapy-naive/experienced.","No serious adverse events, serious infections, treatment-related discontinuations or liver-function abnormalities; 3 drug-related AEs at 20 mg BID (2 fevers, 1 headache).","Plans randomized placebo-controlled Phase 2b monotherapy and Phase 2a OD-001 plus vedolizumab combo; topline induction data expected H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-425684","json":"https://secwatch.observer/filing/0001193125-26-425684.json","markdown":"https://secwatch.observer/filing/0001193125-26-425684.md","text":"https://secwatch.observer/filing/0001193125-26-425684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/0001193125-26-425684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/odtx-20261020.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-20T11:05:20.587906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}